1. Home
  2. UEIC vs IMMP Comparison

UEIC vs IMMP Comparison

Compare UEIC & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Electronics Inc.

UEIC

Universal Electronics Inc.

HOLD

Current Price

$4.77

Market Cap

56.6M

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.42

Market Cap

61.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UEIC
IMMP
Founded
1986
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.6M
61.4M
IPO Year
1995
2012

Fundamental Metrics

Financial Performance
Metric
UEIC
IMMP
Price
$4.77
$0.42
Analyst Decision
Hold
Hold
Analyst Count
1
3
Target Price
$3.50
$5.50
AVG Volume (30 Days)
37.0K
435.8K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
23.78
N/A
EPS
N/A
N/A
Revenue
$368,288,000.00
N/A
Revenue This Year
N/A
$445.09
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.69
$0.29
52 Week High
$7.04
$3.53

Technical Indicators

Market Signals
Indicator
UEIC
IMMP
Relative Strength Index (RSI) 72.97 54.23
Support Level $4.38 $0.42
Resistance Level $5.16 $0.56
Average True Range (ATR) 0.18 0.03
MACD 0.09 0.01
Stochastic Oscillator 89.42 84.24

Price Performance

Historical Comparison
UEIC
IMMP

About UEIC Universal Electronics Inc.

Universal Electronics Inc is engaged in universal wireless control solutions for the home. The company design, develop, manufacture, ship and support climate control solutions, wireless sensor and smart home control products, home entertainment control products, technology and software solutions and audio-video (AV) accessories that are used by the world's brands in the climate control, security, home automation, home appliance, home entertainment and consumer electronics markets.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: